The ACR’s delegation to the American Medical Association’s House of Delegates is gearing up for the HOD Interim Meeting, slated for Nov. 14–18. Several members share their views on the value of this advocacy work and top issues this fall.
The FDA has approved a new drug application for TNX-102 SL (Tonmya), a tablet with 2.8 mg of cyclobenzaprine HCl, after two clinical trials demonstrated the safety and effectiveness of the treatment in adults with fibromyalgia.
The roundtable included discussions on emerging issues in state advocacy, prior authorization reform, likely impacts of the Big Beautiful Bill and physician wellness.
In a recent commentary published by Medscape, ACR President Carol Langford, MD, MHS, issues a stark warning: If Congress does not reform the physician payment system, patients may face increasing difficulty accessing essential medical services.
Teresa J. Brady, PhD, MACR, Basia Belza, PhD, RN, FAAN, FGSA, Kimberly Kimpton, PT, MACR, & Marian T. Hannan, DSc, MPH, MACR |
Four past ARP presidents mark the organization’s 60th anniversary by examining its evolution alongside significant challenges & opportunities in the field.
In a recent op-ed published by MedCity News, rheumatologist and ACR Insurance Subcommittee Chair Michael Feely, MD, delivers a powerful critique of the insurance practice known as white bagging, calling it a “prescription for disruption” that threatens the quality and timeliness of patient care.